Brian R. Edlin, M.D., serves as Associate Professor of Public Health and Medicine at the Weill Medical College of Cornell University, Epidemiologist for the Center for the Study of Hepatitis C in New York, and Senior Principal Investigator at National Development and Research Institutes. Established in 2000 at The Rockefeller University, Weill Medical College and NewYork-Presbyterian Hospital, the Center for the Study of Hepatitis C is a comprehensive, multidisciplinary center dedicated to the study of hepatitis C virus and hepatic disease. Dr. Edlin's research focuses on the clinical epidemiology of hepatitis C, as well as on the epidemiology and primary and secondary prevention of viral hepatitis, HIV infection, overdose, and other infectious and non-infectious health conditions affecting drug users, exploring the effectiveness of harm reduction strategies and evaluating methods to improve their effectiveness.
Dr. Edlin is a fellow of the American College of Physicians, a fellow of the Infectious Diseases Society of America, and a member of the American Association for the study of Liver Disease, and serves on the National Institutes of Health (NIH) HIV Prevention Trials Network Scientific Working Group on Substance Use. He has served on several NIH study sections and has been the recipient of numerous research grants, including eight R-01 awards from the NIH. In 2002, Dr. Edlin was asked to address the NIH Consensus Development Conference on the Management of Hepatitis C as an expert speaker on hepatitis C in injection drug users. The Consensus Panel adopted his recommendations, rescinding the restriction against treating drug users for hepatitis C in the new NIH guidelines, and recommending hepatitis C prevention, testing, and treatment programs for injection drug users and incarcerated persons. Dr. Edlin serves on the New York State Hepatitis C Advisory Council and the Viral Hepatitis and Substance Abuse Treatment Expert Consensus Panel of the U.S. Public Health Service's Center for Substance Abuse Treatment.
Dr. Edlin's current research interests include:
- Clinical and community-based epidemiology of hepatitis C, its pathogenesis, treatment and prevention.
- Epidemiological, clinical, virologic and immunologic characteristics of acute hepatitis C virus infection in injection drug users, correlates of immunity against reinfection.
- Primary and secondary prevention of HIV infection, viral hepatitis, drug overdose, tuberculosis, and other infectious and non-infectious health conditions affecting drug users.
- Qualitative and quantitative research on social, behavioral, and biological factors affecting the health of persons who inject drugs, and strategies for improving their health.
- Evaluation of the effectiveness of harm reduction strategies in clinical and community settings, and development of methods to improve their effectiveness.